Integra LifeSciences Holdings Co. (NASDAQ:IART) Position Increased by Jane Street Group LLC

Jane Street Group LLC raised its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 269.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 224,896 shares of the life sciences company's stock after buying an additional 164,083 shares during the period. Jane Street Group LLC owned about 0.29% of Integra LifeSciences worth $5,101,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of IART. Quadrant Capital Group LLC lifted its holdings in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC lifted its stake in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares in the last quarter. Covestor Ltd increased its position in shares of Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in Integra LifeSciences in the 4th quarter valued at $180,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Trading Down 4.4%

IART stock traded down $0.59 during midday trading on Wednesday, reaching $12.92. 1,505,170 shares of the company's stock traded hands, compared to its average volume of 1,046,197. The business has a 50-day moving average price of $18.59 and a two-hundred day moving average price of $21.81. Integra LifeSciences Holdings Co. has a fifty-two week low of $11.60 and a fifty-two week high of $32.66. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market capitalization of $1.00 billion, a P/E ratio of -143.54, a PEG ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). The company had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. During the same quarter in the prior year, the company posted $0.55 earnings per share. The firm's revenue for the quarter was up 3.7% on a year-over-year basis. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IART. Wells Fargo & Company lowered their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JMP Securities lowered their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. cut their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.